Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Experts Discuss 3 Frequently Overlooked Syndromes

Thomas R. Collins  |  Issue: March 2021  |  March 15, 2021

Zenzen / shutterstock.com

Zenzen / shutterstock.com

ACR CONVERGENCE 2020—Myalgic encephalomyelitis/chronic fatigue syndrome, postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome were the topics of the day in the ever-popular Curbside Consults session in November 2020.

POTS

An anxious woman with a chronic headache and constant myofascial pain in the neck and upper back, assorted gastrointestinal symptoms, chronic severe fatigue, normal lab results and disabled out of proportion with the rest of the clinical picture presents to your clinic. Although your initial thoughts on a diagnosis may turn toward fibromyalgia or conversion disorder, the patient could have POTS, said Tae Chung, MD, assistant professor of physical medicine and rehabil­itation, and director of the POTS program at Johns Hopkins University, Baltimore. 

Dr. Chung

Dr. Chung

“It’s a really common condition, and there’s a pretty good chance you have already seen [such] patients,” he said in an ACR Convergence Curbside Consults session on disorders that can sometimes be overlooked. 

The condition is of increasing interest in rheumatology because emerging evidence suggests it could involve sympathetic function of blood vessels that may have an auto­immune mechanism, Dr. Chung said. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Clinical features of POTS include a severe, profound fatigue, chronic muscle pain and headache, and complaints about nausea and vomiting. Patients may or may not experience palpitations when upright. They may perceive the symptom as discomfort, so clinicians should be careful when interpreting symptoms, Dr. Chung said. POTS usually starts with an infection or traumatic event when the patient is in their late teens or early 20s. 

Blood vessels are innervated by sympathetic nerve fibers that, in their way, pump blood to tissues when needed, such as during exercise or when the body changes position. If this pump mechanism malfunctions, there can be a strong sympathetic response to try to fix the pump, Dr. Chung said. 

Fatigue, dizziness and migraine can be attributed to the pump failure, but other symptoms, such as anxiety, nausea and muscle pain, can be attributed to sympathetic overcompensation, he said. 

Growing evidence indicates autoimmune inflammation can instigate POTS; 40–50% of cases are preceded by an infection, either bacterial or viral, including COVID-19—and ganglionic AChR receptor autoantibody is found in about 5% of POTS patients. Research continues to try to identify other autoantibodies involved, Dr. Chung said. 

Pump failure symptoms may be addressed by aggressive volume expansion (e.g., 4 L water and 4 g sodium daily, scheduled administration of intravenous normal saline), medications (e.g., fludro­cortisone, midodrine) and careful introduction of exercise. Sympathetic overactivity may be treated with low-dose beta blockers, meditation and mindfulness. Dr. Chung emphasized that in some patients, exercise and beta blockade may exacerbate symptoms, so both must be introduced and monitored carefully. 

Although it can be difficult to establish which patients have an autoimmune diathesis, some of these patients may respond to immuno­suppressive or immunomodulatory agents, such as IVIG. 

Page: 1 2 3 | Single Page
Share: 

Filed under:Conditions Tagged with:ACR Convergence 2020mast cell activation syndrome (MCAS)myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS)postural orthostatic tachycardia syndrome (POTS)

Related Articles

    A Rose by Any Other Name: Why clinicians & patients prefer the term myalgic encephalomyelitis & other updates on chronic fatigue syndrome

    September 26, 2017

    A session at the FOCIS 2017 meeting examined the current challenges and understanding of chronic fatigue syndrome, also called myalgic encephalomyelitis, in the hope of stimulating new approaches to deciphering the disease’s mechanistic and immunological underpinnings…

    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Redefined

    June 15, 2015

    A report from the Institute of Medicine that gives new diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and recommends a new name for the disorder received mixed reviews from rheumatologists and other physicians.1 “Diagnosing ME/CFS often is a challenge … the new diagnostic criteria will make it easier for clinicians to recognize and accurately…

    Chronic Fatigue Syndrome: Why Myalgic Encephalomyelitis Is the Preferred Term and More

    October 17, 2017

    CHICAGO—Joseph Breen, PhD, program officer at the National Institutes of Health in Bethesda, Md., opened the chronic fatigue syndrome (CFS) session at the Federation of Clinical Immunology Societies (FOCIS) 2017 meeting by asking presenters to describe the current state of the science to the key immunology stakeholders gathered in the room. The hope was that…

    2015 ACR/ARHP Annual Meeting: Cellular Triggers in Inflammatory Disease

    April 14, 2016

    SAN FRANCISCO—What factors help determine whether or not inflammation resolves, leading to healing, or becomes chronic, leading to disease and tissue destruction? A number of important cells, including toll-like receptors, mast cells, anti-citrullinated protein antibodies, complement and interferon, all play their own role in this process. By understanding how they act in innate and adaptive…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences